# Splisense

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/splisense

- Industry: Biotechnology
- Headquarters: Jerusalem, Israel
- Website: www.splisense.com
- Total disclosed funding: $29M
- Latest round: Series B (May 13, 2021)
- Investors on record: 4

## About

Splisense Ltd. is an innovative biotech firm focused on developing RNA-based therapies utilizing Antisense Oligonucleotides (ASOs) to address serious pulmonary diseases, including cystic fibrosis and idiopathic pulmonary fibrosis.Founded in 2016 and headquartered in Jerusalem, Israel, Splisense specializes in RNA-based therapies, focusing on ASOs to treat genetic pulmonary diseases. The company has completed three deals, with the latest round being a Series B funding of USD 28.5 mn led by Cystic Fibrosis Foundation on May 13, 2021. Gili Hart serves as the CEO, steering the company towards advancing its therapeutic solutions.Splisense specializes in innovative RNA-based therapies utilizing Antisense Oligonucleotides (ASOs) to address pulmonary diseases. The company’s core offerings aim to restore and modify protein functionality by targeting specific genetic mutations that contribute to conditions such as cystic fibrosis, muco-obstructive pulmonary diseases, and idiopathic pulmonary fibrosis (IPF). The ASOs work by modulating gene expression and protein function, thereby providing therapeutic benefits for patients with these challenging conditions. Splisense’s technology is built upon the research of Professor Batsheva Kerem from the Hebrew University, highlighting the effectiveness of ASO-based treatments for genetic diseases. The products are primarily targeted at healthcare providers, hospitals, and research institutions across various geographical markets, including North America and Europe, where there is a substantial need for advanced treatments for pulmonary conditions.Splisense generates revenue through partnerships and collaborations with healthcare providers and research institutions, focusing on B2B transactions. The company's revenue model is centered around the distribution of its ASO therapies, which may involve licensing agreements, collaborative research funding, and milestone payments associated with the achievement of clinical development targets. Clients engage in contractual agreements that establish pricing structures based on the specific products offered, with potential pricing tiers reflecting the stages of development and clinical application of its therapies. Splisense's flagship products, including SPL84, SPL5AC, SPL5B, and SPL23, are integral to its revenue strategy.Following the recent Series B funding of USD 28.5 mn on May 13, 2021, Splisense Ltd. plans to utilize these resources to advance its pipeline, specifically focusing on its lead ASO product, SPL84-23, which aims to treat the 3849+10kb C->T CFTR mutation. The company intends to initiate a Phase 1/2a trial in 2022. Furthermore, Splisense is strategizing to expand its market presence in North America and Europe, targeting an increase in partnerships with healthcare providers and research institutions, thus enhancing accessibility to its therapies.

## Funding rounds

- Series B, May 13, 2021, $29M — OrbiMed Advisors, Integra Holdings, Cystic Fibrosis Foundation, Israel Biotech Fund

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Integra Holdings (https://capitalatlas.ai/funds/integra-holdings) — Series B
- Cystic Fibrosis Foundation — Series B
- Israel Biotech Fund (https://capitalatlas.ai/funds/israel-biotech-fund) — Series B